AureoGen Funding:
AureoGen has to date raised approximately $7.8 million from the following sources:
- $200,000. Start up funding from the Michigan Economic Development Corporation (MEDC), September 4th 2003.
- $1,994,476. A convertible loan from the Michigan Tri-Technology Corridor (MTTC), for development of genetic tools and methodologies for efficient engineering of cyclic peptide producing organisms, June 29th, 2004.
- $162,982. Phase I SBIR grant from the National Institutes of Health (NIH), for a project entitled Novel Antifungals by Engineering a NRPS gene, September 17th, 2004.
- $1,450,508. Three year grant from the National Institutes of Standards and Technology, Advanced Technology Program (NIST/ATP), for a project entitled “A Genetic Engineering Technology Platform for Production of Novel Cyclic Peptide-Based Drugs, September 28th, 2004.
- $225,000. Investment/convertible loan from the Western Michigan University (WMU) Bioscience Research and Commercialization Center (BRCC), April 1, 2005.
- $1,978,701. Three year SBIR grant from the National Institutes of Health (NIH), for Phase II of the project Novel Antifungals by Engineering a NRPS gene, May 15th, 2006.
- $381,116. SBIR Phase I grant entitled, A Bacitracin derivative for systemic use, awarded July 2007.
- $600,000. SBIR Phase I ATP grant (two years) entitled, Generation of novel HCV drugs through engineering of the cssA gene, awarded April 2008.
- $286,746. SBIR Phase I grant entitled, Generation of novel drugs against drug resistant bacterial through engineering a NRPS gene, awarded June, 2008.